DiabetologyNews.net

Diabetology Xagena

Search results for "Jardiance"

The aim of the study was to investigate the long-term safety and efficacy of Empagliflozin ( Jardiance ), a sodium glucose cotransporter 2 inhibitor ( SGLT2 ); Sitagliptin ( Januvia ); and Metformin ( ...


Diabetes mellitus is a leading cause of chronic kidney disease ( CKD ) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macr ...


Empagliflozin ( Jardiance ) has significantly reduced the risk of the combined endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 14% when added to standard of ca ...


Positive top-line results from EMPA-REG OUTCOME were announced. This is a long-term clinical trial investigating cardiovascular ( CV ) outcomes for Jardiance ( Empagliflozin ) in more than 7,000 adult ...


New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo when added to standard of care in people with type 2 diabetes with establis ...


New analyses have shown risk reductions were consistent across age groups for cardiovascular outcomes, including cardiovascular death, with Empagliflozin ( Jardiance ) compared with placebo when added ...